Target | Names of mAb Clones | Intended Application | Mechanisms or Specifications | References |
---|---|---|---|---|
CLDN-1 | 7A5 | DDS | Modulated epidermal barrier | Nakajima et al. (2015) |
CLDN-1 | OM-7D3-B3 | HCV | Prevented HCV entry into hepatocytes by inhibiting CLDN-1 and CD81 interaction. | Fofana et al. (2010) |
5.16 | Hötzel et al. (2011) | |||
3A2 | Fukasawa et al. (2015) | |||
D10X | Paciello et al. (2016) | |||
CLDN-1 | 3A2 | Cancer | Killed tumors through ADCC | Hashimoto et al. (2016b) |
6F6 | Cherradi et al. (2017) | |||
CLDN-2 | 1A2 | IBD | Enhanced barrier strength of inflamed gastrointestinal barrier | Takigawa et al. (2017) |
CLDN-2 | 1A2 | Cancer | Killed tumor through ADCC | Hashimoto et al. (2018a) |
CLDN-3 | KM3953 | Cancer | Killed tumor through ADCC | Ando et al. (2015) |
IgGH6 | Romani et al. (2015) | |||
CLDN-4 | KM3934 | Cancer | Killed tumor through ADCC and enhanced penetration of antitumor drugs into tumor by modulating weak interaction between cancer cells | Suzuki et al. (2009) |
4D3 | Kuwada et al. (2015) | |||
5D12 | Hashimoto et al. (2016a) | |||
Clone 382321 | Torres et al. (2018) | |||
CLDN-4 | HKH-189 | Cell sorting | Sorted minor cell populations from thymocytes and enteroendocrine cells | Kawai et al. (2011) |
Nagatake et al. (2014) | ||||
CLDN-3 and -4 | KM3907 | Cancer | Killed tumor through ADCC | Kato-Nakano et al. (2010) |
5A5 | Li et al. (2014a) | |||
CLDN-5 | R9 | DDS | Enhanced drug penetration into brain by modulating blood-brain barrier | Hashimoto et al. (2017b) |
2B12 | Hashimoto et al. (2018b) | |||
CLDN-6 | IMAB027 | Cancer | Killed tumor through ADCC | Micke et al. (2014) |
CLDN-6 | Clone 342927 | Cell sorting | Sorted residual pluripotent stem cells from differentiated cell populations | Ben-David et al. (2013) |
CLDN-6 | WU-9E1-G2 | HCV | Revealed that these CLDNs could function as HCV entry receptors in nonhepatocyte cell lines but not in hepatocytes | Fofana et al. (2013) |
CLDN-9 | YD-4E9-A2 | |||
CLDN-18.2 | IMAB362 | Cancer | Killed tumor through ADCC | Wöll et al. (2014) |
ADCC, antibody-dependent cellular cytotoxicity; DDS, drug delivery system.